FIELD: chemistry, pharmacology.
SUBSTANCE: present invention relates to new compounds with formula (I), their esters, carbamates and pharmaceutically used salts, which can be used as inhibitors of p38 kinase, which means they can be used for curing diseases and conditions for which p38 is the mediator. In formula (I): Q represents -C(R1R2R3); R1 is chosen from hydrogen, C1-C8 alkyl, hydroxyC1-C8alkyl, and C1-C8alkoxy C1-C8alkyl; R2 and R3 are chosen: (i) independently from: (a) hydrogen, under the condition that, if R1 represents hydrogen, then only one of R2 and R3 can be chosen from hydrogen; (b) C1-C8alkyl; C1-C8alkyl, substituted with one or two radicals halogen, -OR8, -S(O)pR10;(c) -OR8; or (ii) R2 and R3 together with the carbon atom to which they are bonded, form optionally substituted C3-C7cycloalkyl or substituted heterocyclic ring system; R4 and R5 are independently chosen from halogen; R8 and R9 are independently chosen from hydrogen, C1-C8alkyl; R10 represents C1-C8alkyl; m equals 0, n equals 0; and p equals 2; where the term "substituted cycloalkyl" stands for a cycloalkyl group, containing one or two substitutes, which are independently chosen from a group, consisting of -Y-ORs, -Y-S(O)0-2RS, C(=O)ORs, where Y is absent; Rs is independently chosen from hydrogen, C1-C8alkyl, except when the said substitute represents -Y-S(O)1-2Rs, then RS represents hydrogen; the term "heterocyclic ring system" stands for a saturated non-aromatic monocyclic fragment, consisting of 5 to 6 atoms, which are part of the ring system, from which one atom, which is part of the ring system, is a heteroatom, chosen from N, O, and the rest of the atoms in the ring system are carbon atoms; the term "substituted heterocyclic ring system" stands for a heterocyclic fragment mentioned above, containing one substitute, chosen from the group, -Y-Rs, -Y-ORs, -Y-C(O)2Rs, -Y-S(O)0-2Rs, where Y is absent or represents a C1-C4alkylene group, Rs represents the same as was defined above for the substituted cycloalkyl group.
EFFECT: used for treating diseases and conditions.
13 cl, 2 dwg, 5 tbl, 17 ex
Title | Year | Author | Number |
---|---|---|---|
BICYCLIC PYRIDINES AND PYRIMIDINES AS KINASE P38 INHIBITORS | 2003 |
|
RU2301233C2 |
CARBOXYLIC ACID DERIVATIVES CONTAINING 2,5-SUBSTITUTED OXAZOLOPYRIMIDINE RING | 2011 |
|
RU2564018C2 |
DERIVATIVE OF HETEROCYCLIC CARBON ACIDS, WHICH CONTAIN 2,5,7-SUBSTITUTED OXAZOLOPYRIMIDINE RING | 2011 |
|
RU2554869C2 |
NEW BICYCLIC PYRAZOLE DERIVATIVES | 2018 |
|
RU2781426C2 |
6-ALCOXYPYRIDOPYRIMIDINES AND PHARMACEUTICAL COMPOUND POSSESSING ACTIVITY OF MAP p38 KINASE INHIBITORS | 2003 |
|
RU2324695C2 |
CARBOXYLIC ACID DERIVATIVES CONTAINING 2,5,7-SUBSTITUTED OXAZOLE PYRIMIDINE RING | 2011 |
|
RU2560876C2 |
NOVEL IMMUNE SYSTEM MODULATORS RELATED APPLICATIONS | 2012 |
|
RU2606114C2 |
DERIVATIVES OF PYRIDOPYRIMIDINES, METHODS FOR THEIR PREPARING AND PHARMACEUTICAL COMPOSITION BASED ON THEREOF | 2002 |
|
RU2269527C2 |
HDAC INHIBITORS | 2014 |
|
RU2665554C2 |
MONOMER DERIVATIVES OF GLYCOPEPTIDE ANTIBIOTIC | 2005 |
|
RU2424248C2 |
Authors
Dates
2009-05-27—Published
2004-04-08—Filed